Abivax Secures $920M in ADS Offering to Fund Operations Through Q4 2029
ABVX•Abivax raised $920 million by selling 7.36 million American Depositary Shares, including full exercise of the underwriters’ option, generating net proceeds of approximately $874.1 million after commissions and expenses. The capital infusion, combined with current cash reserves, is expected to fund the clinical-stage biotech’s operations into the fourth quarter of 2029.
1. Offering Details
Abivax completed an underwritten public offering of 7.36 million American Depositary Shares, including the full exercise of the underwriters’ option, raising gross proceeds of approximately $920 million prior to commissions and expenses.
2. Net Proceeds and Runway
After underwriting commissions and offering expenses, the company’s net proceeds amounted to approximately $874.1 million, which, combined with existing cash reserves, will fund operations through the fourth quarter of 2029.
3. Strategic Funding Allocation
The capital will primarily support ongoing Phase 3 trials of obefazimod and other clinical programs, as Abivax advances its pipeline of immunoregulatory therapies for chronic inflammatory diseases.
